Clinical readout
OJEMDA Four-Year FIREFLY-1 Results
In the four-year exploratory FIREFLY-1 analysis, median time to next treatment was 50.9 months among 76 efficacy-evaluable patients. Of 41 patients entering post-treatment observation, 76% remained treatment-free for at least 12 months and 54% for at least 24 months; 54% experienced tumor rebound. The safety profile remained consistent with prior findings; grade 3 or higher treatment-related reduced growth velocity occurred in 36% of 137 safety-evaluable patients.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.